40 recruiting. 40 Phase 2, 6 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 40 | Recruiting 40 |
| Phase 1 | 6 | Recruiting 6 |
| Phase 3 | 6 | Recruiting 6 |
Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid Cancer Becotatug Vedotin (MRG003), Lenvatinib, Anti-PD-1 Inhibitor (Continuation of Prior Treatment) - Thyroid Cancer, Tumor | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 39 | 2026-09-20 | 2026-10-14 |
| Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer Selective coverage radiotherapy, comprehensive coverage radiotherapy - Thyroid Cancer | Phase 2 | Recruiting | Fudan University | 72 | 2026-08-12 | 2026-08-20 |
| A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old Felzartamab, Placebo - Graves' Disease | Phase 2 | Recruiting | Biogen | 60 | 2026-07-30 | 2026-10-28 |
| Colchicine for Autoimmune and Subacute Thyroiditis colchicine, Prednisolone, NSAID - Hashimoto Thyroiditis, Subacute Thyroiditis | Phase 2 / Phase 3 | Recruiting | Mansoura University | 300 | 2026-06-15 | 2026-07-29 |
| Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease Experimental: YB-101, Placebo YB-101 - Graves' Disease | Phase 2 | Recruiting | Yarrow Bioscience, Inc. | 232 | 2026-06-10 | 2026-10-30 |
| An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease AMG 732 - Thyroid Eye Disease | Phase 2 | Recruiting | Amgen | 30 | 2026-05-07 | 2026-07-23 |
| A Study of VV-14305 for the Treatment of Thyroid Eye Disease VV-14305, Sham (No Treatment) - Thyroid Eye Disease (TED) | Phase 1 / Phase 2 | Recruiting | Kriya Therapeutics, Inc. | 135 | 2026-05-01 | 2026-08-27 |
| Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease Tofacitinib - Thyroid Eye Disease, TED, Graves Ophthalmopathy | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 8 | 2026-04-24 | 2026-04-29 |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer Iodine-124, Positron Emission Tomography (PET)/Computerized tomography (CT) - Thyroid Cancer | Phase 2 | Recruiting | Thomas Hope | 62 | 2025-12-04 | 2026-06-18 |
| Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC) Lenvatinib - Thyroid Cancer, Cancer of the Thyroid | Phase 2 | Recruiting | Washington University School of Medicine | 34 | 2025-10-14 | 2026-03-17 |
| A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease Rilzabrutinib dose 1, Rilzabrutinib dose 2 - Graves' Disease | Phase 2 | Recruiting | Sanofi | 30 | 2025-09-02 | 2026-10-28 |
| Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery Zanzalintinib - Neoadjuvant Treatment, Thyroid Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 45 | 2025-07-22 | 2026-11-05 |
| A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease IMVT-1402, Placebo - Graves' Disease | Phase 2 | Recruiting | Immunovant Sciences GmbH | 210 | 2025-06-19 | 2026-10-30 |
| XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Recruiting | Jochen Lorch | 33 | 2025-06-06 | 2026-06-26 |
| Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer Tunlametinib, Tunlametinib+PD-1 mAb - Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation, Advanced PDTC or ATC With NRAS Mutation | Phase 2 | Recruiting | Fudan University | 40 | 2025-05-27 | 2025-08-07 |
| MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC MRG003 in combination with pucotenlimab - Thyroid Cancer | Phase 2 | Recruiting | Fudan University | 60 | 2025-04-21 | 2025-11-19 |
| Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) Sacituzumab govitecan - Salivary Gland Cancer, Thyroid Cancer | Phase 2 | Recruiting | National University Hospital, Singapore | 32 | 2025-04-15 | 2025-07-25 |
| Trop2-targeted immunoPET Imaging of Solid Tumors [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4 - Solid Tumor, Solid Carcinoma | Phase 2 / Phase 3 | Recruiting | RenJi Hospital | 400 | 2024-12-23 | 2026-05-29 |
| A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease IMVT-1402, Placebo - Graves' Disease | Phase 2 | Recruiting | Immunovant Sciences GmbH | 240 | 2024-12-17 | 2026-08-25 |
Showing 20 of 40. Sign in to see all of them.
Thyroid Neoplasms (23) · Neoplasms (8) · Graves Disease (6) · Carcinoma, Non-Small-Cell Lung (5) · Graves Ophthalmopathy (5) · Lung Neoplasms (5) · Thyroid Cancer, Papillary (5) · Colorectal Neoplasms (4) · Ovarian Neoplasms (4) · Adenocarcinoma, Follicular (3) · Colonic Neoplasms (3) · Head and Neck Neoplasms (3) · Hyperthyroidism (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3)
Endocrine System Diseases (38) · Endocrine Gland Neoplasms (26) · Head and Neck Neoplasms (24) · Neoplasms by Site (24) · Neoplasms (20) · Immune System Diseases (14) · Autoimmune Diseases (12) · Goiter (11) · Eye Diseases (10) · Neoplasms, Glandular and Epithelial (10) · Orbital Diseases (10) · Exophthalmos (9) · Carcinoma (8) · Digestive System Diseases (8)
Iodine-131 (3) · Magnetic Resonance Spectroscopy (3) · Thyrotropin Alfa (3) · Iodine-124 (2) · Sirolimus (2) · Specimen Handling (2) · Thyroxine (2) · Vemurafenib (2) · X-Rays (2) · cobimetinib (2) · lenvatinib (2) · 130-nm albumin-bound paclitaxel (1) · 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (1) · Anti-Inflammatory Agents, Non-Steroidal (1) · Cetuximab (1)
Fudan University (3) · Cancer Research UK (2) · Children's Hospital of Philadelphia (2) · Immunovant Sciences GmbH (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Amgen (1) · Apollomics Inc. (1) · Biogen (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · City of Hope Medical Center (1) · Haukeland University Hospital (1) · Institut de Recherches Internationales Servier (1) · Jochen Lorch (1) · Kriya Therapeutics, Inc. (1) · M.D. Anderson Cancer Center (1)
United States (24) · China (12) · United Kingdom (8) · Spain (7) · Italy (6) · Australia (5) · Hungary (4) · Poland (4) · Canada (3) · France (3) · Germany (3) · Japan (3) · Singapore (3) · Taiwan (3) · Belgium (2)
Joanna Klubo-Gwiezdzinska, M.D. (2) · Theodore Laetsch, MD (2) · Alan Ho, MD, PhD (1) · Amr A. El Sehrawy, MD, PhD, FRCPE (1) · Brendan Knapp, M.D. (1) · Fangsen Xiao, MD (1) · Francesco Celi (1) · Hans O Ueland, MD Phd (1) · Jianjun Liu, Ph.D. & M.D. (1) · Jochen H Lorch (1) · Lori J. Wirth, MD (1) · Mark Zafereo, MD (1) · Matthew Krebs (1)
PMID 30093503, PMID 32269053, PMID 38197815, PMID 40341199, PMID 41469668, PMID 41495607, PMID 41639379, PMID 42660999
2025 (3), P30CA033572 (1), P30CA060553 (1)